Overview
Syllabus
Intro
Comprehensive NGS-Based DNA Testing at MSKCC
MSK-IMPACT for Tumor Tissue Profiling
Clinical Interpretation of Sequence Variants OnceKB
Automated Monitoring for Precision Oncology Clinica
MSK-IMPACT Data Sharing Paradigm
Additional Features Revealed Through TIN Sequencin
Clinical Germline Assessment
Inferring Cancer Risk Through T/N Sequencing Tumor DNA
Prevalence of Clonal Hematopoiesis
Clonal Hematopoiesis Clinic at MSKCC
How Do Germline Variants Influence Somatic Phenoty
Prevalence of Pathogenic Mutations by Cancer Type
Prevalence of Biallelic Inactivation by Cancer Type
Many cancer are independent of the germline allele
Germline Contributions to Clonal Hematopoiesis?
Limitations of Tissue-Based DNA Sequencing
Genomic Profiling Using Plasma Cell-free DNA CFDNA
Rare Variant Detection: Ultra-Deep Sequencing & Erra Suppression
MSK-ACCESS for Plasma cfDNA Profiling
Clinical Implementation of MSK-ACCESS at MSK - Approved by NYS Department of Health in May 2019
Importance of Sequencing Matched Normal WBCs Identify and eliminate garming and clonal hematopoinsis variants
Polyclonal Acquired Resistance is commonly Observ
Additional Examples of Polyclonal Resistance Mutatic
Ongoing work: Increase sensitivity for detecting ctDN
Patients with Lynch Syndrome Develop MSI-H Tumors
Detecting MSi in cDNA Using MSK-ACCESS
Future Prospects for Clinical Sequencing • Incorporate more genes, non-coding regions, viral DNA
Acknowledgements: Molecular Diagnostics Service
Acknowledgements (Part 2)
Taught by
Stanford Radiology